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The innate immune response is initiated by the interaction of stereotypical pathogen components with genetically conserved
receptors for extracytosolic pathogen-associated molecular patterns (PAMPs) or intracytosolic nucleic acids. In multicellular
organisms, this interaction typically clusters signal transduction molecules and leads to their activations, thereby initiating signals
that activate innate immune eﬀector mechanisms to protect the host. In some cases programmed cell death—a fundamental
form of innate immunity—is initiated in response to genotoxic or biochemical stress that is associated with viral infection. In
this paper we will summarize innate immune mechanisms that are relevant to viral pathogenesis and outline the continuing
evolution of viral mechanisms that suppress the innate immunity in mammalian hosts. These mechanisms of viral innate immune
evasion provide significant insight into the pathways of the antiviral innate immune response of many organisms. Examples of
relevant mammalian innate immune defenses host defenses include signaling to interferon and cytokine response pathways as
well as signaling to the inflammasome. Understanding which viral innate immune evasion mechanisms are linked to pathogenesis
may translate into therapies and vaccines that are truly eﬀective in eliminating the morbidity and mortality associated with viral
infections in individuals.
1. Introduction
The innate immune system is as ancient as the bacterial
immune response to bacteriophages. As the nature and
complexity of viral innate immune evasion mechanisms
evolved, so has the innate—and eventually adaptive—
immune response to these mechanisms. The innate immune
response in mammals is initiated by the interaction of
stereotypical pathogen components with germ-line encoded
receptors. In some cases, signal transduction pathways are
stimulated in sentinel cells, such as macrophages and den-
dritic cells. Stimulation of these signaling pathways promptly
activates innate eﬀector mechanisms to protect the host;
these innate immune signals also activate antigen-presenting
cells that are critical to the eventual adaptive immune
response of the host [1]. In this paper we will summarize
findings in the innate immune system that are relevant to
viral pathogenesis and outline the evolution of viral mech-
anisms that suppress innate immunity in mammalian hosts.
2. The Innate Immune System
The receptors of the innate immune system are germ-
line encoded and include the nucleotide-binding domain
leucine-rich repeat containing receptors, the Toll-like recep-
tors (TLRs), and the RIG-I-like receptors (RLRs). The RLRs
are cytosolic sensors of pathogen RNA and include proteins
encoded by the retinoic acid-inducible gene-I (RIG-I) [2],
the melanoma diﬀerentiation-associated gene 5 (MDA5)
[3, 4], and the laboratory of genetics protein 2 (LGP2)
[4] and DDX3, which is thought to associate with RIG-
I [5]. The helicase domains of RLRs detect the cytosolic
RNA of microbial pathogens, generating signals that drive
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production of cytokines and interferons. Helicases are ATP-
dependent enzymes that unidirectionally translocate along
a transcript thereby dissociating nucleic acid duplexes [6].
The RIG-I and MDA5 RLRs play critical roles in the
recognition of foreign RNA and in the response to many viral
pathogens. MDA5 and RIG-I contain a DExD/H-box RNA
helicase domain and caspase activation and recruitment
domains (CARDs). RIG-I recognizes 5′-triphosphate RNA,
and MDA5 can recognize complex webs of pathogen RNA,
comprised of both viral single-stranded and double-stranded
RNA [2]. The LGP2 RLR protein was found to lack a
CARD domain and was originally identified as a dominant
negative inhibitor of RIG-I signaling [7]. Under some
circumstances, though, it appears LGP2 can stimulate RLRs
such as MDA5 and RIG-I [8]. CARD engagement leads to
interaction with a protein known as mitochondrial antiviral
signaling protein (MAVS) that is alternatively designated
CARDIF, HELICARD, or IPS-1 (referred to here as MAVS)
[9, 10]. Subsequently, upon oligomerization, MAVS signals
to members of the IKK family of kinases that are critical for
the innate immune response [10]. Thus MAVS induces IKKα
and IKKβ stimulation that leads to translocation of NF-κB,
as well as IKKε/TBK1 stimulation that leads to translocation
of IRF-3. These transcription factors stimulate production of
cytokines, other innate immune response proteins, and type
I interferons [4].
Extracytosolic innate immune sensing of pathogens is
mediated via the TLRs. Humans are known to encode ten
TLRs which are each involved in the recognition of diﬀerent
pathogen-associated molecular constituents [11]. The TLRs
are transmembrane receptors found on the cell surface
and/or associated with endocytic vesicles [11]. Thus, they are
ideally situated to detect extracytosolic pathogens. For exam-
ple, TLR4 is required for the recognition of Gram-negative
bacterial lipopolysaccharide (LPS, or endotoxin) while TLR3
is able to recognize dsRNA, a signature compound common
in the lifecycle of many viruses, while TLR7 and 8 recognize
ssRNA [12]. Toll/IL-1 interacting receptor (TIR) adapters
ultimately stimulate IkB family kinases (IKKs) often via
transducing proteins such as IRAKs and TRAFs, thereby
mediating signaling originally induced by engagement of
TLRs that ultimately activates NF-κB and IRF3 [13].
Two classical IKKs, IKKα and IKKβ, are critical for
NF-κB activation. They function, in large part, by phos-
phorylating the inhibitors of NF-κB, known as IkBs. Once
phosphorylated, IkBs are ubiquitinated and degraded. This
allows NF-κB subunits to translocate to the nucleus and
activate target gene expression. NF-κB is critical for driving
the expression of numerous cytokines, chemokines, and
costimulatory molecules, creating an inflammatory response
[14]. On the other hand, the two nonclassical IKK family
members, IKKε and TBK1, are implicated in IRF3 activation.
In particular, they are believed to directly phosphorylate
several serine residues within the C-terminal activation
domain of IRF3. Once phosphorylated, IRF3 dimerizes and
translocates to the nucleus where it activates target gene
expression [15]. IRF3 activation is critically important for the
activation of type I interferons, either directly [16] or via an
autocrine/paracrine loop [17, 18]. Type I interferons, in turn,
are capable of inducing a significant antiviral response in the
host [2, 13, 19].
Cells also encode cytosolic DNA sensors which detect
DNA, which is not typically present in the cytosol and
thus a pattern whose recognition signals the presence of
viral nucleic acids. Nucleotide oligomerization domain-like
receptor proteins (NLRs) are implicated in the intracytosolic
recognition of sterile inflammatory instigators, such as urate
crystals, intracytosolic DNA, or viral RNA. One such NLR,
nucleotide oligomerization domain-like receptor protein 3
(NLRP3) is an inflammasome component that signals to the
apoptosis-associated speck-like protein containing a caspase
recruitment domain (ASC) to induce the clustering-induced
self-processing of procaspase 1 into caspase 1 which then
digests the precursor form of pro-IL-1β and pro-IL-18 to
permit release of the inflammatory cytokines IL-1β and
IL-18 from the cell [20]. Similar inflammatory pathways are
triggered by engagement of other cytosolic DNA sensors such
as AIM-2, another NLR that ultimately induces cleavage of
procaspase 1 into caspase 1. Aim-2 can detect the molecular
patterns of intracellular hazards such as pathogen DNA,
particularly that of poxviruses [21]. Other NOD proteins
which are alternatively designated NACHT, LRR, and PYD
function as sensors of toxic intracellular molecules including
cytosolic DNA [22]. Thus the NLRs represent examples of
cytosolic DNA sensors capable of inducing an inflammatory
antiviral response.
Another antiviral cytosolic sensor is the DNA-dependent
activator of interferon (DAI), which binds B- and Z-form
DNA, thereby recognizing intracytosolic viral DNA. Signals
from such sensors are transduced by known innate immune
kinases such as TBK1, which interacts with a protein known
as stimulator of interferon genes (STINGs) to activate NF-
κB and IRF3 signaling [10, 23, 24]. Finally, it is assumed
that there is at least one other pathway for the detection
of the dsDNA of microbes, based in part on DNA sensing
in cells despite absence of the DAI pathway [25]. The
known receptors for viral DNAultimately induce interferons,
cytokines, and programmed cell death pathways.
Apoptosis is the programmed death of dangerous or
unnecessary cells, for example, virally infected, aging, or
malignant cells. It is thus one of the most ancient forms
of innate immunity. Certain cellular bcl-2 proteins mediate
resistance to programmed cell death (apoptosis) [50–52],
typically via interaction with proapoptotic bcl-2-related
proteins [52]. Human bcl-2 also leads to increased nuclear
translocation of the transcription factor, NF-κB [53–55],
which typically promotes cell survival [14, 56, 57]. Other
cellular bcl-2 proteins promote cell death in response to
harmful stimuli such as viral infection. Other eﬀectors of
programmed cell death are caspases. Cleavage of cellular
caspases and/or loss of mitochondrial integrity promote cell
death in the face of many stimuli including viral infection.
Still other death programs include pyroptosis—the death
of cells following activation of the PYRIN domains and
IL-1 release. Thus, in the absence of viral innate immune
evasion, apoptosis provides an antiviral mechanism for the
elimination of virally infected cells.
Advances in Virology 3
Table 1: Examples of parallel evolution of viral innate immune evasion mechanisms.
(a) Bacteria
Mechanism Viral evasion strategy Virus protein
CRISPER Genetic variation of DNA DNA polymerase [26]
Psp-induced signaling Unknown (Psp genetic variation) Unknown
Restriction/methylation Methylation of viral target DNA
Acquired bacterial methylase
[26]
Apoptosis Lysogeny/tolerance Phage lysis gene regulation [27]
(b) Drosophila
Mechanism Evasion strategy Viral protein
DICER1 Genetic variation of DNA Virus encodes miRNAs [28]
Vago IkB, Jak/Stat inhibitors Viral IkB, unknown inhibitor of Jak/STAT [29]
DICER2 Binding of ds RNA FHV-B2 protein [30]
Apoptosis Inhibitor of apoptosis (IAP) Baculovirus p35 [31, 32]
(c) Mammalian systems
Mechanism Evasion strategy Viral protein
Interferon signaling
dsRNA binding
Influenza virus NS1 [33], VACV E3 (also
inhibits DNApol III DNA sensing) [34]
Inhibition of signaling
VACV N1 family [5, 35–37], HCV NS3A/4
[38], influenza virus NS1 [33], HCV core
proteins inhibit Jak/Stat signaling [39],
HCV NS5A inhibits MyD88 [40],
HIV Vif, and Vpr degrade IRF3 [37]
Inhibition of IFN binding VACV soluble IFN alpha/beta receptors [41]
Viral RNA/DNA sensing
Inhibitors of RIG-I HCV NS3A/4 proteolytic cleavage of MAVS
[38, 42]
Inhibitors of MDA5, LGP2
Paramyxovirus V proteins [43]
Inhibitors of DDX3
VACV K7 [5]
Inhibitors of the AIM2/NLRP3
Inflammasome KSHV vNLR [44], myxoma virus M013 [45]
Inhibitors of proteins activated
downstream of the AIM2/NLRP3
inflammasome
Cowpox virus crmA
VACV SPI-2, sIL-1βR, and sIL-18R [41]
DAI EBV EBERmiRNAs [25]
Programmed cell death
Viral inhibitor of apoptosis (IAP) KSHV vFLIP [46]
Viral bcl-2s
EBV bhrf1 and balf1 [47, 48],
KSHV orf16 [49]
Blockade of IL-1-mediated pyroptosis
Poxvirus crmA, sIL-1β, sIL18 [41]
3. Evolution of the Antiviral
Innate Immune Response: Different Genes,
Recurring Themes
Prokaryotic organisms encode primordial proteins that
recognize the molecular patterns (e.g., specific sequences
of DNA of bacteriophages) from pathogens (i.e., bacterio-
phages) and thus can be considered to possess a primitive
innate immune system. Although the mechanisms of innate
immunity in bacteria diﬀer radically from those of higher
organism, four principles of innate immunity are preserved
in several mechanisms (Table 1). First, the clustered regularly
space short palindromic repeats (CRISPERs) of bacteria and
archaea encode a series of palindromic sequences that target
pathogen DNA and suppress their transcription in a way
similar to the antiviral action of microRNAs of Drosophila
[58, 59]. Second, following exposure of prokaryotes to bacte-
riophages, the phage shock protein (Psp) signaling pathway
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involves an unknown sensor and signal transduction by
the leucine zipper protein PspB. PsP signaling is initiated
in response to loss of cell membrane integrity induced
by stresses such a bacteriophage infection [60]. This is
similar in principle to the enhanced cell membrane integrity
mediated by interferon in the mammalian antiviral response
[2, 13, 19]. A third conserved principle is intracytosolic
nucleic acid recognition (analogous to mammalian RLRs or
DrosophilaDICER) that triggers an innate immune response.
In bacteria, restriction endonucleases recognize and digest
bacteriophage nucleic acids, while specificity of this response
is maintained by bacterial methylation of its native DNA.
Fourth, programmed death of bacteriophage-infected bac-
teria induced by the MazF protein can pre-empt spread of
viral infection, as is true of proapoptotic proteins in higher
organisms (reviewed in [27]). Bacteriophage mechanisms
to evade the bacterial innate immune pathways include
rapid mutation to generate DNA sequence diversity that
evades CRISPER, acquisition of host bacterial methylases
to mask restriction sites in bacteriophage DNA [26], and
programmed cell death resistance [27]. A bacteriophage
mechanism to evade PsP signaling has not been reported,
although it is tempting to speculate that the rapid muta-
tion observed during bacteriophage infection might avoid
detection by the Psp pathway. Although the details and
evolution of innate immunemechanisms in bacterial cells are
highly divergent from multicellular organisms (Table 1), the
principal functional attributes of innate immune recognition
and viral evasion are remarkably conserved, especially in the
invertebrate innate immune responses.
Drosophila lack an adaptive immune system; thus, they
are ideal model organisms to study innate immunity since
they possess a complex innate immune system (Table 1).
Viral mechanisms for suppression of innate immunity in
Drosophila have been reviewed recently and will be dis-
cussed only briefly here [29]. In contrast to mammalian
cells, Drosophila does not encode NOD proteins. It has
been suggested that Drosophila TLRs encoded recognize
PAMPs of viruses that are tropic for Drosophila [61]. Unlike
mammals, Drosophila rely heavily on RNA interference as
a defense against viruses. The protein DICER2 is a heli-
case/endonuclease that is related to the RIG-I-like helicase
of mammals [62]. DICER2 has two eﬀector functions; the
first initiates a cascade of endonucleolytic cleavage of viral
RNAs that mediate gene silencing, and the second is a RIG-I-
like signaling activity of DICER2 whereby DICER-2 mediates
induction of the antiviral genes, such as Vago [62]. A distinct
protein, DICER1, cleaves isolated miRNAs that subsequently
suppress transcription of viral RNA just as mammalian
DICER2 does [58, 59]. To evade this innate immune defense,
the Flockhouse virus encodes the dsRNA-binding protein B2
that inhibits dsRNA recognition by DICER1 and DICER2 in
Drosophila [30]. Furthermore, viruses inhibit the function of
inhibitors of kappaB (I-κB) translocation to prevent signal-
ing initiated by Drosophila TLRs [61], but not the Jak/Stat
antiviral defense pathway in Drosophila. Other viral proteins
that act in signal transduction are thought to mediate the
production of antiviral peptides, including the principal
Drosophila gene induced by viral infection that is Vago,
which encodes a 14 kilodalton cysteine-rich polypeptide
[62]. Vago is thought to be, in principle, analogous to
interferons as it is a virus-induced protein critical to control
viral infection. Finally, viral innate immune evasion proteins
encoded by baculovirus inhibit the function of apoptotic
pathways [31, 32, 63, 64]. Although there are parallels
between the principles of innate immune defense against
viruses between bacteria and Drosophila (Table 1), the innate
immune responses ofDrosophilamore closely resemble those
of the mammalian antiviral innate immune response.
4. Viral Evasion of Host Defenses:
Highlighting Critical Components of the
Mammalian Innate Immune Response
4.1. DNA Viruses. The Poxviridae are large enveloped DNA
viruses that replicate in the cytoplasm. Vaccinia virus
(VACV) is a robust poxviral vaccine originally used to
eradicate smallpox. Poxviruses encode approximately 180
genes. About 80 genes are essential for replication in tissue
culture, whereas 100 encode virulence proteins, such as decoy
receptors for IL-1, TNF-α, and interferons. These virulence
proteins (Table 1, bold text, and Figure 1) interdict innate
immune signaling by preventing receptor engagement at the
cell surface [65]. Moreover, the pox virus proteins, E3 and
K3, bind dsRNA in the cytoplasm, reducing type I interferon
production and, in the case of E3, preventing activation of
the dsRNA-dependent protein kinase PKR [34].
Other vaccinia virus proteins have been characterized as
inhibitors of innate immune intracellular signal transduction
(Figure 1). For example the VACV N1 family of ten bcl-2
like proteins inhibits NF-κB signaling [37]. Of the proteins
characterized to date, N1 is the most robust VACV virulence
factor, increasing replication 10,000-fold, inhibiting NF-κB,
IRF3 and apoptotic signaling [35, 66, 67]. A52 inhibits
NF-κB and increases p38 kinase activity [68]. A46 inhibits
NF-κB and IRF3 signaling [36]. And K7 inhibits IRF3 and
NF-κB signaling by binding to DDX3 and preventing MAVS
signaling to TBK1 [5]. It is unclear what the role of N1’s anti-
apoptotic function is as VACV already encodes a vbcl-2 (F1),
that, unlike N1, is critical for viral survival in vitro. Thus,
the antiapoptotic potential of the N1 vbcl-2 reconciles the
absence of cell death despite N1 inhibition of NF-κB. While
no direct inhibitor of the inflammasome has been detected in
vaccinia virus, the poxvirus serpins SPI-1 and crmA inhibit
caspase 1 activity downstream of the inflammasome [69]
and another poxvirus, myxoma virus encodes the M013
PYRIN domain containing protein that inhibits signaling
by the inflammasome by interrupting association of NLRP3
and ASC ([45], see Figure 2). Thus poxviruses inhibit many
aspects of the two-signal inflammasome inflammatory path-
way by inhibiting pro-IL-1β and pro-IL-18 production by the
IKK pathway and cleavage by the inflammasome (Figure 2).
Additionally, as outlined in Figure 1, IKK complex signaling
to TNF-α, IFN, and other cytokines is impaired by viral
innate immune evasion proteins.
The gammaherpesviruses encode proteins that highlight
the role of antiapoptotic factors in innate immune evasion.
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Figure 1: Signaling by the innate immune system that is inhibited by several viral proteins. This model depicts the salient features of
TLR-induced NF-κB and IRF3 induction. Several poxviral proteins N1, C6, A14 A46, and A52 inhibit the activation of NF-κB and/or
IRF3 signaling pathways, by interacting with and inhibiting the activity of the classical IKK complex (IKKα/β/γ) as well as the nonclassical
IKKε/TBK1 complex. HCV protein NS5A inhibits TIR signaling by MyD88, its NS3/4A digests MAVS to inhibit RLR signaling, and its core
protein inhibits Jak/Stat signaling. Finally, HIV Vif and Vpr degrade IRF3.
Herpesviruses cause a latent, life-long infection. During
latent infection herpesvirus antigens are principally present
in the nucleus thereby evading recognition by the cytoso-
lic and extranuclear membrane-associated components of
the innate immune system. The apoptotic mechanisms
of the innate immune system aﬀect the elimination of
herpesvirus-infected cells. Two human gammaherpesviruses,
Epstein Barr Virus (EBV) and Kaposi’s Sarcoma Herpesvirus
(KSHV) have evolved several mechanisms that induce latent
infection and thus inhibit the apoptotic innate immune
response (LMP1 and LANA1). Recent studies of recombinant
EBV containing deletions of the genes encoding both the
antiapoptotic vbcl-2, BHRF1 [47], and a second EBV bcl-2,
BALF1 [48, 70, 71], have revealed that deletion of both
EBV bcl-2 homologs dramatically increases the survival of
cells undergoing EBV infection [72]. Finally, the KSHV
gammaherpes orf63 has been shown to encode a viral NLR
(vNLR, Figure 2) that inhibits NLRP1, NLRP3, and NOD2
function, permitting persistent KSHV infection [45].
Viral caspase inhibitors are believed to neutralize
immune responses of the host that activate the caspase
pathway of apoptotic cell death (although it is logical
to hypothesize that viral caspase 1 inhibitors also inhibit
the inflammasome). Three diﬀerent viral proteins inhibit
the caspase pathway of apoptosis: (1) the serpins of
the poxviruses, exemplified by crmA, a caspase inhibitor
encoded by the cowpox virus genome [69], and (2) the
baculovirus p35 caspase inhibitor protein [73]. Finally, the
v-FLIPs, which are expressed by the gammaherpesviruses
equine herpesvirus 4 and Kaposi’s Sarcoma Herpesvirus
(KSHV/HHV-8) [46] inhibit apoptosis by competing with
caspase 8 (FLICE) for binding to the death eﬀector domains
of adaptor proteins of death receptors (reviewed by [74]).
Inhibition of the activation of the caspase cascade that would
otherwise follow oligomerization of death receptors prevents
apoptosis induced by the cascade of proteases that eventually
induce cellular self-digestion [75]. Inhibition of caspases
is thus another evolutionarily conserved mechanism for
viruses to avoid the apoptotic host innate immune response.
In addition, vFLIPs dysregulate the function of IKK-γ,
thereby activating the IKK complex-mediated dissociation
of IkB from NF-κB and subsequent NF-κB signaling [76].
Activation of the IKK cascade that would otherwise promote
innate immune signaling activates KSHV replication and
promotes KSHV-transformed cell survival. In the case of this
KSHV mechanism, signaling by the classical innate immune





















































Figure 2: Viral proteins inhibit nucleic acid receptors of the intracytosolic innate immune response. Viruses inhibit each of the two signals
that initiate the inflammasome activation process. The first signal—IL-1β and/or IL-18 binding and activation of the TLR/IL-1β receptor
pathway—is inhibited by soluble IL-1β and IL-18 (from VACV); downstream, inhibitors of signaling to NF-κB (from VACV or HCV)
repeatedly target this important antiviral pathway that optimally requires NF-κB translocation leading to the production of pro-IL-1β and
pro-IL-18. Second, the inflammasome processes these pro-IL-1β and pro-IL-18 proteins via caspase-1 that is itself processed upon clustering
mediated at the NLRP3 inflammasome upon detection of intracytosolic pathogens. This leads to IL-1β and IL-18 production and release that
activates the IL-1β/IL-18 pathway in an autocrine manner, as well as the innate and adaptive immune response. Inflammasome activation is
inhibited by myxoma virus M013, measles viruses V protein, and KSHV vNLR. Finally signaling to IRF3 by intracytosolic DNA or RNA is
inhibited at the level of MAVS by HCV’s NS3/4A and at the level of TBK1 by VACV C6 and N1 (Figure 1).
response pathway is perturbed by KSHV protein, allowing
KSHV to escape the apoptotic host innate immune response.
4.2. RNA Viruses. Hepatitis C Virus (HCV) is a single-
stranded, positive-sense RNA virus that encodes 10 proteins.
HCV typically induces a life-long infection via successfully
evading the adaptive and innate immune responses. The
manyHCV proteins that possess dual functions in both repli-
cation and innate immune evasion likely reflect the limited
number of HCV. Surprisingly for the small size of its genome,
HCV shares mechanisms of innate immune evasion with
much larger DNA viruses such as the poxviruses. Poxvirus
nucleoside triphosphate phosphohydrolase I (NPH-I) is
absolutely essential for VACV mRNA transcription and
VACV replication, yet simultaneously NPH-I inhibits the
interferon response [77]. The HCVNS3/4A protease/helicase
encodes a helicase that suppresses the IFN-β promoter
independently of NS3/4A proteolytic destruction of innate
immune signaling components such as TRIF that activate
the IFN-β [42]. A recombinant RLR engineered to encode
only a helicase domain is a dominant negative inhibitor
of RLR-driven interferon (IFN)-β promoter activity. This
dominant negative RLR lacks a signaling domain [7]. Viral
helicases inherently lack signaling domains, and thus viral
helicases structurally resemble a dominant negative RLR
and might act as RLR antagonists. HCV innate immune
evasion mechanisms also include the proteolytic destruction
of MAVS by the protease component of the NS3/4A protein.
The destruction of MAVS, which transduces signals from the
RLRs, therefore inhibits signaling to IRF3 via TBK1, blocking
the interferon response. HCV core protein expression corre-
lates with impaired signaling of the Jak/Stat pathway to IFN-
α/β, although the mechanism for this is still being defined
[78]. The HCV core protein inhibits TLR signaling through
its chronic stimulation of TLR2 resulting in TLR hypore-
sponsiveness [79], HCV core protein binds STAT1, and HCV
infection leads to STAT1 degradation, which inhibits the
antiviral signaling in the Jak/Stat pathway [80]. Finally HCV
protein NS5A inhibits recruitment of IRAK to the MyD88
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TIR adapter [40] and may inhibit interferon production via
NS5A suppression and the phosphorylation of eIF2 by the
PKR kinase [40]. Thus, HCV inhibits several types of innate
immune signaling via the action of only a few proteins.
Influenza viruses are enveloped RNA viruses with a
negative-sense, single-stranded segmented genome. Influ-
enza virus is an extremely virulent respiratory pathogen,
and influenza virus possesses distinct innate immune evasion
mechanisms that are critical for its pathogenesis. The
nonstructural protein-1 (NS1) functions to inhibit the host
interferon response [81], thus inhibiting activation of IRF3
[35, 81]. Deletion NS1 dramatically attenuates influenza
viruses [35, 81]. Inhibition of RLR signaling is a critical
event in the lifecycle of many viral pathogens, for example,
influenza virus [82, 83]. Influenza NS1 protein inhibits RIG-
I signaling to NF-κB and IRF3 by inhibiting the E3 ubiquitin
ligase TRIM 25 required for its function [33]. Furthermore,
influenza virus NS1 binds to dsRNA that would trigger
the RIG-I/MDA5 antiviral response. Finally, the influenza
virus polymerase activity depends upon cellular mRNA,
thereby depleting host mRNAs, which has been postulated
to inhibit host antiviral gene expression [45]. Similar to
herpesviruses, influenza virus undergoes replication in the
nucleus minimizing detection by intracytosolic nucleic acid
sensors dsRNA binding by the influenza. Thus, influenza
virus appears to encode inhibitors of nucleic acid sensing,
host antiviral gene expression, interferon response, dsRNA,
and physical separation of signal transduction components
from the innate immune sensors. These mechanisms are a
recurrent theme in viral innate immune evasion.
Retroviruses are highly successful at evading innate
and adaptive immune responses. The rapid evolution
of HIV envelope proteins and their heavy glycosylation
results in epitopes that are not conducive to an adaptive
immune response. The well-studied mechanisms for retro-
viral immune evasion include the infection and apoptotic
destruction of HIV-1- or HIV-2-infected T cells. It is
interesting to note that HIV protease degrades human bcl-
2 [84] and that HIV Nef, an HIV accessory’ protein, induces
apoptosis [85]. Thus this mechanism of HIV induction of
apoptosis breaks the typical paradigm where viruses encode
proteins that inhibit apoptosis (see Table 1).
HIV encodes several other “accessory” proteins that are
essential for HIV infectivity and pathogenesis in vivo. These
proteins antagonize the innate immune response in several
ways. Nef mediates activation of MAPK signaling to AP-1,
which is suggested to activate viral replication [86, 87].
HIV Vif and Vpr degrade IRF3, thereby inhibiting signaling
to IRF3 and interferon production [88]. Thus, although
inhibition of adaptive immunity by HIV is well known,
innate immune evasion plays an important role in HIV
pathogenesis.
5. Conclusion: Innate Immunoevasion—From
Insight to Innovation
Many viral mechanisms have evolved to evade the immune
response. Surprisingly, the general outline of innate antiviral
mechanism is remarkably persistent throughout evolution,
such as DNA restriction/dicing and programmed cell death;
however, diﬀerences between innate immune responses of
distinct organisms are often more striking and may hint at
novel innate immune evasion pathways still undiscovered in
mammalian virus-host interactions. Signaling to interferon
resembles antiviral protein induction in Drosophila and in
some respects, even in bacteria. The evolutionary conserva-
tion of these mechanisms suggests their study will advance
understanding of viral pathogenesis and that these pathways
would be worthy targets of antiviral inhibitors.
In this regard, there are several promising antiviral
therapies targeting viral innate immunoevasion genes. HCV
protease inhibitors have been suggested to inhibit HCV
innate immunoevasion, presumably by preventing MAVS
digestion [38, 89], and thereby permitting critical signaling
to interferon. An in vitro study of the N1 vaccinia virus
virulence factor and innate immune evasion protein iden-
tified chemical inhibitors of its antiapoptotic function [90].
This is surprising as N1 does not mediate cell death in vitro,
where these inhibitors were tested [91, 92]. These findings
highlight the diﬃculty of studying certain innate immune
inhibitors in vitro. Nevertheless, targeting potent virulence
factors of viral pathogens represent a promising and entirely
new approach to antiviral drug design—beyond drugs that
exclusively target viral enzymes responsible for replication.
Perhaps the most promising application of these studies is
in the development of highly immunogenic live vaccines
that contain deletions of innate immune evasion genes
outlined here. Such vaccine would have the potential to be
safer and potentially more immunogenic vaccine viruses by
virtue of their attenuated ability to mediate innate immune
suppression.
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STING: Stimulator of interferon genes
CRISPR: Clustered regularly sPaced short palindromic
repeats
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HCV: Hepatitis C virus
NPH-I: Poxvirus nucleoside triphosphate
phosphohydrolase I
IFN: Interferon
NS1: Nonstructural protein 1
DDX3: DEAD/H Box 3
IKK: Inhibitor ofkappa-B kinase
TBK: TANK-binding kinase 1
IRAK: IL-1 receptor-associated kinase-1
IRF3: Interferon response factor 3
IL: Interleukin
AIM-2: Absent in melanoma-2
TRIM 25: Tripartite motif-containing protein 25.
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